1192129-25-1

Upstream product

• 81109-72-0 1'-benzyl-6-bromospiro[chroman-2,4'-piperidin]-4-one 
• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1286738-33-7 C₂₀H₂₂BrNO 
• 1192129-24-0 (E)-3-{1'-benzyl-spiro[chromane-2,4'-piperidine]-6-yl}-acrylic acid methyl ester 

Downstream Products

• 1192131-62-6 (E)-N-hydroxy-3-{1'-benzylspiro[chromane-2,4'-piperidine]-6-yl}acrylamide trifluoroacetate 

Relevant academic research and scientific papers

Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors

New spiro[chromane-2,4′-piperidine] and spiro[benzofuran-2,4′- piperidine] hydroxamic acid derivatives as HDAC inhibitors have been identified by combining privileged structures with a hydroxamic acid moiety as zinc binding group. The compounds were evaluated for their ability to inhibit nuclear extract HDACs and for their in vitro antiproliferative activity on different tumor cell lines. This work resulted in the discovery of spirocycle 30d that shows good oral bioavailability and tumor growth inhibition in an HCT-116 murine xenograft model.

Spirocyclic derivatives as histone deacetylase inhibitors

This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; R1 is hydrogen; C1-C6 alkyl, optionally substituted by aryl or by heteroaryl; (CO)R3; (SO2)R4; aryl; or heteroaryl; R2 is C1-C6 alkyl, optionally substituted by aryl or by heteroaryl; aryl; heteroaryl; or (CO)R5; X is CH2, oxygen or NR6; Y is a bond, CHR7 or NR8; Z is oxygen, CR9R10 or C=R11; and R3, R4, R5, R6, R3 R8, R9, R10 and R11 are as further defined in the specification; and pharmaceutical acceptable salts thereof.